<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384891</url>
  </required_header>
  <id_info>
    <org_study_id>102.1</org_study_id>
    <nct_id>NCT00384891</nct_id>
  </id_info>
  <brief_title>Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer</brief_title>
  <official_title>A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Enterprises Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Enterprises Europe B.V.</source>
  <brief_summary>
    <textblock>
      The study is designed to compare the efficacy and safety of 2 treatment types for the&#xD;
      prevention of tumor recurrence of superficial bladder cancer:&#xD;
&#xD;
        1. A combination of bladder wall heating and local chemotherapy (Synergo)&#xD;
&#xD;
        2. Bacillus Calmette-Guérin (BCG)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized controlled study, designed to test the efficacy and safety of a new&#xD;
      treatment modality for the prevention of tumor recurrence in superficial bladder cancer.&#xD;
&#xD;
      Patients must have their tumors surgically resected prior to study enrollment, and undergo a&#xD;
      series of tests to prove their bladder is now free of tumor. Eligible patients will be&#xD;
      randomly assigned to one of 2 treatment arms:&#xD;
&#xD;
        1. A combination of bladder wall heating and local chemotherapy (Synergo)&#xD;
&#xD;
        2. Bacillus Calmette-Guérin (BCG)&#xD;
&#xD;
      Patients will be treated during the first year of the study, and will be followed up for a&#xD;
      total of 2 years. The follow up will include a visual evaluation of the patient's bladder by&#xD;
      cystoscopy, a cytological examination of the urine (to look for malignant cells) and other&#xD;
      additional exams. The patients' general welfare will be monitored through out the study.&#xD;
&#xD;
      The aim of this study is to compare the efficacy and safety of the novel treatment (Synergo)&#xD;
      to that of the well-known BCG&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrence free survival probability of STCCB in patients with pure (non-CIS) papillary tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of complete response in CIS patients</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression rate (to disease stage&gt;T1) and/or metastatic disease</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and systemic side effects, both subjective and objective</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Urinary Bladder Diseases</condition>
  <condition>Urinary Bladder Neoplasms</condition>
  <condition>Urinary Bladder Cancer</condition>
  <condition>Malignant Tumor of Urinary Bladder</condition>
  <condition>Urologic Diseases</condition>
  <condition>Urologic Neoplasms</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasms by Site</condition>
  <arm_group>
    <arm_group_label>Synergo + MMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacillus Calmette-Guérin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravesical instillation with BCG (Bacillus Calmette-Guérin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synergo + MMC</intervention_name>
    <description>Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C</description>
    <arm_group_label>Synergo + MMC</arm_group_label>
    <other_name>RITE</other_name>
    <other_name>SHTC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacillus Calmette-Guérin</intervention_name>
    <description>Intravesical instillation with BCG (Bacillus Calmette-Guérin)</description>
    <arm_group_label>Bacillus Calmette-Guérin</arm_group_label>
    <other_name>BCG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Superficial TCC: Any G3 or any T1 and/or CIS&#xD;
&#xD;
          -  Multifocal (&gt;1) Ta lesions&#xD;
&#xD;
          -  Multiple recurrences (&gt;2) of Ta lesions in the last 24 months&#xD;
&#xD;
          -  Complete tumor eradication must be confirmed&#xD;
&#xD;
          -  WHO performance status 0-2 (Appendix V)&#xD;
&#xD;
          -  Life expectancy of more than 24 months&#xD;
&#xD;
          -  Patients willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bladder tumors other than TCC&#xD;
&#xD;
          -  Coexistence of another primary malignant tumor other than BCC of the skin&#xD;
&#xD;
          -  TCC of the bladder involving the urethra or upper urinary tract&#xD;
&#xD;
          -  Previous history of TCC stage T2 or higher&#xD;
&#xD;
          -  Clinical presence or previous history of regional spreading or distant metastases&#xD;
&#xD;
          -  Intravesical MMC treatments during the last 12 months&#xD;
&#xD;
          -  Previous intravesical BCG therapy (Any intravesical BCG therapy in the last 24 months,&#xD;
             or More than 6 BCG intravesical instillations in the last 48 months.&#xD;
&#xD;
          -  Previous pelvic radiotherapy or systemic chemotherapy&#xD;
&#xD;
          -  Partial cystectomy&#xD;
&#xD;
          -  Diverticle of bladder larger than 1cm in diameter&#xD;
&#xD;
          -  Residual urine &gt; 100cc measured by uroflowmetry&#xD;
&#xD;
          -  Bladder volume &lt; 150cc measured by ultrasound&#xD;
&#xD;
          -  Urinary incontinence (more than one wet pad a day)&#xD;
&#xD;
          -  Urethral stricture impeding 20F catheterization&#xD;
&#xD;
          -  Urethral bleeding or persistent hematuria&#xD;
&#xD;
          -  Active intractable or uncontrollable UTI&#xD;
&#xD;
          -  Active tuberculosis or BCG infection&#xD;
&#xD;
          -  Patients who experienced BCG life threatening sepsis&#xD;
&#xD;
          -  Known allergy to MMC or BCG&#xD;
&#xD;
          -  Known impaired immune response, positive HIV serology, patients receiving systemic&#xD;
             steroids or immunosuppressive therapy&#xD;
&#xD;
          -  Hematological disorders; leukocytes &lt; 3500, platelets &lt; 100,000&#xD;
&#xD;
          -  Kidney or liver function disorders (more than 1.5 times upper normal limit)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients who cannot be followed up properly or are unable to collaborate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfred A Witjes, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Radboud University Hospital, Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital - AKH Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Hospital</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galliera Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo del Oncologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital (HSR)</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Radboud University Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>October 5, 2014</last_update_submitted>
  <last_update_submitted_qc>October 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial urothelial cell carcinoma of bladder</keyword>
  <keyword>NMIBC</keyword>
  <keyword>Non Muscle Invasive Bladder Cancer</keyword>
  <keyword>Hyperthermia</keyword>
  <keyword>Bladder instillation</keyword>
  <keyword>Mitomycin C</keyword>
  <keyword>RITE</keyword>
  <keyword>SHTC</keyword>
  <keyword>Intravesical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

